secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001493152-22-006294
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO
--------------------------------------------------------------------------------

- Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.
- Gregory Berk ceases role as Interim CEO but remains President of R&D and CMO; base salary increased to $437,750.
- Both appointments effective March 2, 2022; no other officer changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-006294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer